Jean Popovici1, Lindsey Pierce-Friedrich2, Saorin Kim1, Sophalai Bin1, Vorleak Run1, Dysoley Lek3, Kim Hor Daryl Hee4, Lawrence Lee Soon-U4, Matthew V Cannon2,5, David Serre2,5, Didier Menard1,6. 1. Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom Penh. 2. Genomic Medicine Institute, Cleveland Clinic, Ohio. 3. National Center for Malaria Control, Phnom Penh, Cambodia. 4. National University of Singapore. 5. Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore. 6. Malaria Genetics and Resistance Group, Biology of Host-Parasite Interactions Unit, Institut Pasteur, France.
Abstract
Background: Plasmodium vivax resistance to chloroquine (CQ) has been reported worldwide, although the World Health Organization clinical drug efficacy studies protocol does not permit classification of patient outcomes. Methods: We enrolled 40 patients with P. vivax malaria in northeastern Cambodia, where >17% treatment failures were previously reported. Patients were treated with CQ (30 mg/kg) and followed for 2 months, with frequent clinical examination and capillary blood sample collection for microscopy, molecular parasite detection and genotyping, and drug concentration measurements. Reinfections were prevented by relocating patients to a transmission-free area. Results: P. vivax parasites were eliminated in all patients by day 3. Genomic analyses revealed that all clones in polyclonal infections were cleared at the same rate, indicating their equal susceptibility to CQ. CQ blood concentrations were below the therapeutic level in all recurrent infections (24 of 40 patients), which were efficiently cleared by a second course of CQ treatment. Genotyping (128 SNPs barcode) and sequences of entire parasite genome (Whole-Genome Sequencing, Illumina) indicated that two thirds (6 of 8) of the recurrent parasites resulted from heterologous relapses whose 50% are from by sibling/recombinant clones. Conclusions: No evidence of CQ resistance was observed. Our data suggest that P. vivax antimalarial drug resistance is likely overestimated and that the current guidelines for clinical drug studies of P. vivax malaria need to be revised.
Background: Plasmodium vivax resistance to chloroquine (CQ) has been reported worldwide, although the World Health Organization clinical drug efficacy studies protocol does not permit classification of patient outcomes. Methods: We enrolled 40 patients with P. vivax malaria in northeastern Cambodia, where >17% treatment failures were previously reported. Patients were treated with CQ (30 mg/kg) and followed for 2 months, with frequent clinical examination and capillary blood sample collection for microscopy, molecular parasite detection and genotyping, and drug concentration measurements. Reinfections were prevented by relocating patients to a transmission-free area. Results:P. vivax parasites were eliminated in all patients by day 3. Genomic analyses revealed that all clones in polyclonal infections were cleared at the same rate, indicating their equal susceptibility to CQ. CQ blood concentrations were below the therapeutic level in all recurrent infections (24 of 40 patients), which were efficiently cleared by a second course of CQ treatment. Genotyping (128 SNPs barcode) and sequences of entire parasite genome (Whole-Genome Sequencing, Illumina) indicated that two thirds (6 of 8) of the recurrent parasites resulted from heterologous relapses whose 50% are from by sibling/recombinant clones. Conclusions: No evidence of CQ resistance was observed. Our data suggest that P. vivax antimalarial drug resistance is likely overestimated and that the current guidelines for clinical drug studies of P. vivax malaria need to be revised.
Authors: James G Kublin; Joseph F Cortese; Eric Mbindo Njunju; Rabia A G Mukadam; Jack J Wirima; Peter N Kazembe; Abdoulaye A Djimdé; Bourema Kouriba; Terrie E Taylor; Christopher V Plowe Journal: J Infect Dis Date: 2003-05-21 Impact factor: 5.226
Authors: André M Siqueira; Marcus V G Lacerda; Belisa M L Magalhães; Maria P G Mourão; Gisely C Melo; Márcia A A Alexandre; Maria G C Alecrim; Dhanpat Kochar; Sanjay Kochar; Abhishek Kochar; Kailash Nayak; Hernando del Portillo; Caterina Guinovart; Pedro Alonso; Quique Bassat Journal: BMC Med Date: 2015-03-20 Impact factor: 8.775
Authors: Nicholas M Douglas; Gysje J Pontororing; Daniel A Lampah; Tsin W Yeo; Enny Kenangalem; Jeanne Rini Poespoprodjo; Anna P Ralph; Michael J Bangs; Paulus Sugiarto; Nicholas M Anstey; Ric N Price Journal: BMC Med Date: 2014-11-18 Impact factor: 8.775
Authors: Douglas H Kerlin; Kane Boyce; Jutta Marfurt; Julie A Simpson; Enny Kenangalem; Qin Cheng; Ric N Price; Michelle L Gatton Journal: PLoS Negl Trop Dis Date: 2012-08-07
Authors: Antonio A S Balieiro; Andre M Siqueira; Gisely C Melo; Wuelton M Monteiro; Vanderson S Sampaio; Ivo Mueller; Marcus V G Lacerda; Daniel A M Villela Journal: Int J Environ Res Public Health Date: 2021-05-11 Impact factor: 3.390